WO2008093646A1 - Wntシグナル伝達系活性化ペプチド - Google Patents

Wntシグナル伝達系活性化ペプチド Download PDF

Info

Publication number
WO2008093646A1
WO2008093646A1 PCT/JP2008/051224 JP2008051224W WO2008093646A1 WO 2008093646 A1 WO2008093646 A1 WO 2008093646A1 JP 2008051224 W JP2008051224 W JP 2008051224W WO 2008093646 A1 WO2008093646 A1 WO 2008093646A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
stem cell
activity
acid sequence
Prior art date
Application number
PCT/JP2008/051224
Other languages
English (en)
French (fr)
Inventor
Masao Tanihara
Kazumi Kajiwara
Original Assignee
National University Corporation NARA Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation NARA Institute of Science and Technology filed Critical National University Corporation NARA Institute of Science and Technology
Priority to JP2008556089A priority Critical patent/JPWO2008093646A1/ja
Publication of WO2008093646A1 publication Critical patent/WO2008093646A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

　本発明は、分子量が比較的小さく、神経幹細胞や造血幹細胞等の幹細胞の増殖や分化制御；或いは癌、神経疾患、糖尿病等の疾病の治療に有用なペプチド又はその塩を提供することを課題とする。 　以下の(1)又は(2)に示すペプチド、又はその塩を提供する：(1)配列番号１で表されるアミノ酸配列からなるペプチド、(2)配列番号１で表されるアミノ酸配列において1又は数個のアミノ酸が置換、欠失、若しくは付加されたアミノ酸配列からなり、且つ、PC12細胞の接着誘導活性、神経幹細胞の分化促進活性、及び細胞内βカテニン蓄積促進活性よりなる群から選択される少なくとも１種のWntシグナル伝達系活性化作用を有するペプチド。
PCT/JP2008/051224 2007-02-01 2008-01-28 Wntシグナル伝達系活性化ペプチド WO2008093646A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008556089A JPWO2008093646A1 (ja) 2007-02-01 2008-01-28 Ｗｎｔシグナル伝達系活性化ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-023073 2007-02-01
JP2007023073 2007-02-01

Publications (1)

Publication Number Publication Date
WO2008093646A1 true WO2008093646A1 (ja) 2008-08-07

Family

ID=39673957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051224 WO2008093646A1 (ja) 2007-02-01 2008-01-28 Wntシグナル伝達系活性化ペプチド

Country Status (2)

Country Link
JP (1) JPWO2008093646A1 (ja)
WO (1) WO2008093646A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
JP2020506701A (ja) * 2017-01-26 2020-03-05 スロゼン， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
US11993645B2 (en) 2018-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
WO2005040351A2 (en) * 2003-10-24 2005-05-06 California Institute Of Technology Compositions for inducing cell growth and differentiation and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
WO2005040351A2 (en) * 2003-10-24 2005-05-06 California Institute Of Technology Compositions for inducing cell growth and differentiation and methods of using same
WO2005040347A2 (en) * 2003-10-24 2005-05-06 California Institute Of Technology Methods and compositions for inhibiting cell growth and proliferation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
JP2014521685A (ja) * 2011-08-04 2014-08-28 ケアジェン カンパニー，リミテッド Ｗｎｔ系列由来のペプチド及びこれの用途
EP2740741A4 (en) * 2011-08-04 2015-08-05 Caregen Co Ltd PEPTIDE OBTAINED FROM THE WNT FAMILY AND USES THEREOF
JP2016029061A (ja) * 2011-08-04 2016-03-03 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途
EP3037433A1 (en) * 2011-08-04 2016-06-29 Caregen Co., Ltd. Wnt family-derived peptides and use thereof
JP2017008030A (ja) * 2011-08-04 2017-01-12 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途
EP3121196A1 (en) * 2011-08-04 2017-01-25 Caregen Co., Ltd. Wnt family-derived peptides and use thereof
JP2020506701A (ja) * 2017-01-26 2020-03-05 スロゼン， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
US11958891B2 (en) 2017-01-26 2024-04-16 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
US11993645B2 (en) 2018-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules

Also Published As

Publication number Publication date
JPWO2008093646A1 (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2455461A3 (en) Lipase variants for pharmaceutical use
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
EP2476699A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2005115306A3 (de) Keratin-bindende polypeptide
EP2940042A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
EP2039367A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
WO2010103070A3 (en) Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2007019860A3 (en) Gdnf derived peptides
WO2002061076A1 (en) Adiponectin-associated protein
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2008093646A1 (ja) Wntシグナル伝達系活性化ペプチド
WO2007071248A3 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
WO2009068042A3 (en) Novel peptides derived from ncam (fgls)
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
WO2008099928A1 (ja) 蛋白質分解酵素活性を調節する作用を有する胎盤蛋白質及びその関連遺伝子
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
WO2005005469A3 (en) Novel purified polypeptides from staphylococcus aureus
WO2003066849A3 (en) Novel purified polypeptides from staphylococcus aureus
WO2009069546A1 (ja) 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704033

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008556089

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08704033

Country of ref document: EP

Kind code of ref document: A1